H.C. Wainwright Reiterates Buy Rating on Alpha Tau Medical Ltd. (DRTS)

Wed, 21 Oct 2026 06:48:44 -0400

H.C. Wainwright analyst Yi Chen reiterated a Buy rating and $16.00 price target on Alpha Tau Medical Ltd. (NASDAQ: DRTS).

The analyst commented: "REGAIN enrollment doubles to 20 patients; new data to be presented at Society for Neuro-Oncology annual meeting. Yesterday, Alpha Tau Medical announced the FDA approval of an Investigational Device Exemption (IDE) supplement expanding its REGAIN trial in recurrent glioblastoma (GBM) from 10 to 20 patients across three U.S. centers, with additional study endpoints and interim analysis. According to management, the expanded study could generate data that may support future market submission requirements. Of note, this prospective, interventional, open-label,

Form 6-K Alpha Tau Medical Ltd. For: Oct 19

Mon, 19 Oct 2026 10:25:00 -0400

si-local-file:///var/storage/secattach/20261019/27202257.html

FDA clears Alpha Tau to double enrollment in glioblastoma trial

Mon, 19 Oct 2026 08:30:18 -0400

Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) announced that the U.S. Food and Drug Administration has approved an Investigational Device Exemption supplement allowing the company to expand its REGAIN trial, a study evaluating its Alpha DaRT device for the treatment of recurrent glioblastoma, from 10 to 20 patients.

The updated protocol also opens enrollment to patients with IDH-mutant grade 4 tumors, adds progression-free survival as a secondary endpoint, introduces regular quality-of-life assessments, and includes an additional interim analysis scheduled six months after the fifth patient's treatment, which occurred in July 2026. The trial is being conducted at three U.S. academic cancer

Alpha Tau Announces FDA Approval to Expand Alpha DaRT® U.S. Recurrent Glioblastoma REGAIN Trial; New Trial Data to be Presented at SNO 2026 Annual Meeting

Mon, 19 Oct 2026 08:30:00 -0400

- FDA approves IDE supplement expanding REGAIN from 10 to 20 patients, with additional study endpoints and interim analysis -

- Abstract authored by REGAIN study principal investigator Dr. Joshua Palmer of The Ohio State University accepted for presentation at the Society for Neuro-Oncology (SNO) 2026 Annual Meeting, marking the trial’s first appearance at a scientific meeting -

- Glioblastoma is the most common malignant primary brain tumor in the U.S. -

JERUSALEM, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) (“Alpha Tau”), the developer of

Alpha Tau Announces FDA Approval to Expand Alpha DaRT® U.S. Recurrent Glioblastoma REGAIN Trial; New Trial Data to be Presented at SNO 2026 Annual Meeting

Mon, 19 Oct 2026 08:30:00 -0400

- FDA approves IDE supplement expanding REGAIN from 10 to 20 patients, with additional study endpoints and interim analysis -

- Glioblastoma is the most common malignant primary brain tumor in the U.S. -

JERUSALEM, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) (“Alpha Tau”), the developer of

Alpha Tau to Participate in October Investor Conferences

Mon, 05 Oct 2026 09:45:00 -0400

JERUSALEM, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that company management will participate in the following investor conferences in October 2026.

Form 4 Alpha Tau Medical Ltd. For: Aug 21 Filed by: Levy Raphi

Tue, 25 Aug 2026 10:34:00 -0400

si-local-file:///var/storage/secattach/20260825/26972627.html

Form 4 Alpha Tau Medical Ltd. For: Aug 21 Filed by: Levy Raphi

Tue, 25 Aug 2026 10:34:00 -0400

si-local-file:///var/storage/secattach/20260825/26972627.html

Form 144 Alpha Tau Medical Ltd. Filed by: Levy Raphi

Fri, 21 Aug 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260821/26962322.html

Form 144 Alpha Tau Medical Ltd. Filed by: Levy Raphi

Fri, 21 Aug 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260821/26962322.html

Nano Dimension names Nadav Kidron to board, to chair new committee